skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Jason Donville just released his Q3 newsletter:

http://www.donvillekent.com/pdf/DKAM-Newsletter-October2015.pdf

It's always a great read, but I thought your readers may be interested in what he has to say regarding CXR. Please note this is the last paragraph of a lengthy discussion in the newsletter:

"So, where to from here? CXR has completed its equity issue and its underlying businesses are strong. But we also know the company is carrying more debt than we would like. Going forward, we think the stock is still quite undervalued but the company will need to address its debt issue somewhere down the road. This could mean that the company raises more equity or puts itself up for sale. Regardless, at current valuations, I think the company is worth a lot more than $50 a share. On our numbers, CXR trades on 4.8x 2016 Cash Earnings and 1.1x BVPS, while earning a 24% ROE."
Read Answer Asked by Arneh on October 08, 2015
Q: I currently don't have any exposure to the healthcare sector. Would you please make a couple of recommendations.
Thank you
Read Answer Asked by Rose on October 07, 2015
Q: Hi, Peter publish at own will.
No comments

A quick run on numbers (US) Health care

EPS growth
q2 15 8%
Q1 15 10%
q4 14 11.8%
q3 14 12.4%

Revenue growth
Q2 15 11.6%
Q1 15 17.6%
q4 14 22.3%
q3 14 16.3%
Read Answer Asked by claude on October 06, 2015
Q: Hi, Peter For info only, publish at will
Another reason Health Care was weak Monday, was the passing of the TPP (or Trans Pacific Patrnership), which according to The Hill, a Beltway newsletter which provides daily updates,

” Trade officials from 12 countries agreed Monday to shrink the length of time that pharmaceutical companies can receive monopoly rights for certain drugs, a provision that is already threatening to incite a Big pharma rebellion on Capitol Hill…Brand-name companies would receive up to eight years of monopoly rights for drugs known as biologics — a decrease from the current 12 years provided under U.S. law, according to officials involved. The final language of the deal has not yet been released.”
Read Answer Asked by claude on October 06, 2015
Q: Hi Peter,

I bought this stock at 11.49, is it ok to average down based on this news of should I wait.

Thanks,
Paul
Read Answer Asked by PAUL on October 05, 2015
Q: Both Concordia and Valeant are down 8.5 and 10% respectively at the moment. Is this due to normal volatility or any consequence of the TPP deal? Would you consider either a bargain over the next three years and which one would you prefer?
Thank you.
Read Answer Asked by Steven on October 05, 2015
Q: Hello Peter & Co,
A follow-up on my previous question regarding your ranking of my holdings CRH,CXR,GUD,PHM,PLI,RX and VRX; you ranked GUD,CXR and VRX as the best by a wide margin and that PLI is good but expensive; you did not comment on or ranked CRH, PHM and RX
Thanks,
Antoine
Read Answer Asked by Antoine on October 05, 2015
Q: Just wandering about the recent pullback in these two stocks do you think it's just collateral damage from Hilary's remarks or are the underlying stories still intact,would you consider this a buying opportunity at these levels thanks Greg.
Read Answer Asked by Greg on October 05, 2015
Q: Hi, Valeant's share price took huge hit over past two weeks, after Hilary Clinton comments and Democrats' request for a subpoena for drug pricing. There are two drugs in question, where price increases were 225% and 550% appx. As per analysts covering the stock, even if price of these two drugs is reversed, it should impact the share price by about $8-$9. Except one major brokerage, no one has changed rating of the stock (Most have Buys). Although a few have adjusted price targets between $10-$15 but average is still about CAD$325. Last week stock traded as low as $204.50 and has now stabilized in $230-$240 range. Only a few weeks ago it traded as high as $347. Despite the near term headline risk (although it is not known if house committee will even accept the democrats request for a subpoena and US history of very limited success with drugs price control), is it reasonable to accumulate shares at these levels, in your view? Valeant still appears to be the only choice in large cap pharma sector in Canada (of course Concordia being the other)and I am wondering if there is an opportunity here. Thanks, as always for your valued comments.
Read Answer Asked by rajeev on October 05, 2015
Q: Hello Peter & Co,
10% of my portfolio is in that sector
CRH,CXR,GUD,PHM,PLI,RX and VRX
With the intent to shifting funds from what I perceive to be lower ranked to higher ranked ones, I would appreciate your input.
Thanks,
Antoine
Read Answer Asked by Antoine on October 05, 2015
Q: Hi- just thought my fellow subscribers who own Valeant might be interested in this article, which, in brief, states that Valeant is one of the greatest increasers of drug prices and may be affected by the Hilary Clinton furor.
http://www.zerohedge.com/news/2015-10-04/more-pain-biotechs-ahead-valeants-astronomical-price-increases-take-center-stage-pfi
Read Answer Asked by Pat on October 05, 2015
Q: Hi Guys,

I have owned JNJ for many years and it really has not performed up to my expectations.

Would you sell JNJ today and replace it with UnitedHealth Group (UNH)for a 5 year hold. I require something to stay in the drug/healthcare area of my portfolio.

If yes, could you give me your reasons.

Thanks for the help.

Regards
John
Read Answer Asked by John on October 02, 2015
Q: Hello Peter & Co.
9% of my portfolio is in Health/Pharma and the above are my main holdings; I was ready to pull the plug on both of them early this week but I held steady.
If I did not own them and wanted to buy either one; which would you suggest I buy and why and when?
I appreciate the fact that you hold the line despite the treacherous movements of the market.
Thanks,
Antoine
Read Answer Asked by Antoine on October 01, 2015
Q: Yesterday,shortly before the market close,a reporter on BNN when commenting on Concordia's share issue stated "clearly this issue will have to be repriced" or words very close to this quote.My question is:Do you consider the above quote to be appropriate considering the attack to which this stock has been subjected?I can understand an analyst or a money manager making such a statement but for a BNN reporter it seems to me to be irresponsible.The statement seemed to have no effect on the stock price but not long after CXR reported that the issue was completed and the money was"in the bank".Publish at your discretion.I thank you for your continued guidance and advice. Don.
Read Answer Asked by Donald on September 30, 2015
Q: Good morning

Can you please give me your updated thoughts on NDQ as an investment.
It seems to have been unfairly caught up in biotechnology paranoia.

Thanks once again for the tremendous service!

Tom
Read Answer Asked by Thomas on September 30, 2015
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!